drugset / Trial / NCT02126826

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1026706 in Male and Female Healthy Subjects and Patients With Osteoarthritis of the Knee

NCT02126826

Phase 1 Completed 58 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

* To investigate the safety and tolerability of BI 1026706 in male and female healthy subjects and osteoarthritis (OA) patients following oral administration of repeated rising doses * To explore the pharmacokinetics after multiple rising doses of BI 1026706 in male and female healthy subjects and OA patients * The assessment of pharmacodynamics in OA patients

Timeline

Start
2014-05-28
Primary completion
2014-10-01
Completion
2014-10-21

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1026706 Unknown Oral

Indications